Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 15;2(10):1101–1114. doi: 10.1182/bloodadvances.2017015404

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society of Hematology

PMC Copyright notice

Figure 3. — Expression of NKp30, NKp46, and CD161 consistent with an adaptive NK cell phenotype. NK cell subsets, including CD56^brightCD16^neg (1), CD56^brightCD16^pos (2), CD56^dimCD16^pos (3), and CD56^negCD16^pos (4), were evaluated for each group of children: Nandi (EBV^low/malaria^low), Kisumu (EBV^high/malaria^high), and eBL patients with low EBV and high EBV load. Comparison of NKp30 (A) and NKp46 (B) expression on the different NK cell subsets across all study groups. NKp30 (C) and NKp46 (D) expression on CD56^negCD16^pos NK cell subsets across study groups. Nandi, n = 10; Kisumu, n = 8; and BL, n = 11 for NCRs. (E) Comparison of CD161 on the different NK cell subsets across all study groups. (F) CD161 expression on the CD56^negCD16^pos NK cell subset across study groups. Nandi, n = 8; Kisumu, n = 8; and BL, n = 11 for CD161 expression. Data are mean ± SD. *P < .05, **P < .01, ***P < .001.